Meta-analysis of ciprofloxacin in treatment of Crohn's disease

Wu, Xiaowei; Ji, Hanxu; Wang, Fangyu

doi:10.3892/br.2014.368

Cited by 21 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect disappeared with the discontinuation of antibiotic therapy at week 24. A recent published meta‐analysis combining the three above‐mentioned studies revealed that ciprofloxacin was effective in achieving remission in patients with Crohn's perianal fistula (pooled relative risk = 1.66; 95% CI 1.16–2.39; P = 0.006) . Immunomodulators are recommended in the medical management of perianal CD, but there are no comparative studies and indirect evidence is derived from secondary end‐points in clinical trials.…”

Section: Resultsmentioning

confidence: 99%

Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines

et al. 2016

View full text Add to dashboard Cite

show abstract

“…80 In these 2 settings, it may be that secondary bacterial overgrowth (in an area of a sinus tract or anastomosis) may perpetuate chronic inflammation, in which case antibiotic therapy may ameliorate symptoms. Some studies suggest that specific antibiotics improve disease severity, [81][82][83] although these studies are not always reproducible and often use symptomatic endpoints without measurement of inflammatory parameters. It is possible that decreasing the overall bacterial burden via antibiotics decreases symptoms such as diarrhea or bloating, which subsequently reduces disease activity scores, without necessarily improving the mucosal inflammation.…”

Section: Clinical Use Of Fmt For Ibdmentioning

confidence: 99%

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

2017

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex set of diseases that lead to chronic inflammation in the gastrointestinal tract. Although the etiology of IBD is not fully understood, it is well-known that the intestinal microbiota is associated with the development and maintenance of IBD. Manipulation of the gut microbiota, therefore, may represent a target for IBD therapy. Fecal microbiota transplantation (FMT), where fecal microbiota from a healthy donor is transplanted into a patient's GI tract, is already a successful therapy for Clostridium difficile infection. FMT is currently being explored as a potential therapy for IBD as well. In this review, the associations between the gut microbiota and IBD and the emerging data on FMT for IBD will be discussed.

show abstract

“…None of the patients was receiving anticoagulants or antiplatelet agents before the procedure. All patients received the same antibiotic prophylaxis: 5 days of ciprofloxacin (500 mg twice daily) starting 24 h before the biopsy (11). Moreover, all patients received a povidone-iodine aqueous solution enema starting fifteen minutes before the TRUSBx (12).…”

Section: Methodsmentioning

confidence: 99%

Safety of transrectal ultrasound-guided prostate biopsy in patients affected by Crohn’s disease

Dell’Atti

Galosi

2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

Purpose: Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract. It is usually considered a contraindication to transrectal ultrasound-guided prostate biopsy (TRUSBx). The aim of this study was to investigate the safety of TRUSBx in a small cohort of patients with CD. Methods: We queried our institutional database clinical data of patients with a diagnosis of CD undergoing TRUSBx, and a retrospective prospective study of 5 patients was planned. All patients enrolled were in the remission phase of CD and asymptomatic. They received the same antibiotic prophylaxis and a povidone-iodine aqueous solution enema before the procedure. A standardized reproducible technique was used with using a ultrasound machine equipped with a 5-9 MHz multifrequency convex probe “end-fire”. The patients were treated under local anaesthesia, and a 14-core biopsy scheme was performed in each patient as first intention. After the procedure each patient was given a verbal numeric pain scale to evaluate tolerability of TRUSBx. Results: TRUSBx was successfully completed in all patients. The number of biopsy cores was 14 (12-16). Of the 5 biopsy procedures performed 40% revealed prostatic carcinoma (PCa) with a Gleason score 6 (3+3). No patients required catheterization or admission to the hospital for adverse events after the procedure. The most frequent adverse event was hematospermia (60%), while hematuria was present in 20% of patients and a minimal rectal bleeding in 20% of the patients. No patients reported severe or unbearable pain (score ≥ 8). Conclusions: This study suggests that CD may not be an absolute contraindication to TRUSBx for prostate cancer detection, but still requires a careful patients selection.

show abstract

Meta-analysis of ciprofloxacin in treatment of Crohn's disease

Cited by 21 publications

References 28 publications

Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines

Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines

Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease

Safety of transrectal ultrasound-guided prostate biopsy in patients affected by Crohn’s disease

Contact Info

Product

Resources

About